Literature DB >> 10606965

Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour?

E Louis1, M Peeters, D Franchimont, L Seidel, F Fontaine, G Demolin, F Croes, P Dupont, L Davin, S Omri, P Rutgeerts, J Belaiche.   

Abstract

Crohn's disease (CD) is a multifactorial disease with genetic heterogeneity. TNF-alpha plays a key role in the development of the mucosal lesions. The aim of our work was to study a single base pair polymorphism located in the promoter region of TNF gene, in a large population of CD patients with well defined phenotypes. One hundred and ninety-three patients with CD and 98 ethnically matched controls were studied. The -308 single base pair polymorphism of TNF gene was studied using an allele-specific polymerase chain reaction. Genotype and allelic frequencies were compared between patients and controls and between subgroups of patients defined by sex, age at diagnosis, familial history, location of disease, type of disease, extra-intestinal manifestations, and response to steroid treatment. In 29 patients a measure of TNF-alpha production by colonic biopsies was performed. The frequency of the allele TNF2 as well as the proportion of carriers of the allele TNF2 were slightly but not significantly lower in CD than in controls (11.9% versus 14.8% and 21.5% versus 27.6%, respectively). A more prominent difference in frequencies of allele TNF2 and in proportions of TNF2 carriers was found when comparing subgroups of patients. The frequency of allele TNF2 was significantly higher in steroid-dependent than in non-steroid-dependent disease (28.1% versus 10.3%; Delta = 17.8%, 95% confidence interval (CI) = 6.3-29.5%, P = 0.0027) and tended to be higher in colonic than in small bowel disease and in fistulizing than in stricturing disease. Furthermore, TNF2 carriers tended to be more frequent in patients with steroid-dependent than non-steroid-dependent disease (43.8% versus 19.3%; Delta = 24.5%, 95% CI = 3.6-45.4%, P = 0.022), in patients with fistulizing than stricturing disease (26.5% versus 9.6%; Delta = 16.9%, 95% CI = 1. 1-32.6%, P = 0.036), and in patients with colonic than small bowel disease (26.5% versus 11.1%; Delta = 15.4%, 95% CI = -0.8-31.6%, P = 0.063). Finally, patients carrying at least one copy of allele 2 were found to produce slightly more TNF-alpha at the colonic level. The -308 TNF gene polymorphism may have a slight influence on the behaviour of CD. The carriage of allele 2 may favour steroid-dependent disease and to a lesser extent fistulizing and colonic disease, possibly secondary to a more intense TNF-alpha-driven inflammatory reaction at the mucosal level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10606965      PMCID: PMC1905519          DOI: 10.1046/j.1365-2249.2000.01106.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

Authors:  W A Stack; S D Mann; A J Roy; P Heath; M Sopwith; J Freeman; G Holmes; R Long; A Forbes; M A Kamm
Journal:  Lancet       Date:  1997-02-22       Impact factor: 79.321

2.  Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid.

Authors:  D J Conway; M J Holland; R L Bailey; A E Campbell; O S Mahdi; R Jennings; E Mbena; D C Mabey
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  HLA-DRB1*03, but not the TNFA -308 promoter gene polymorphism, confers protection against fistulising Crohn's disease.

Authors:  G Bouma; A C Poen; M A García-González; G M Schreuder; R J Felt-Bersma; S G Meuwissen; A S Pena
Journal:  Immunogenetics       Date:  1998-05       Impact factor: 2.846

4.  Mapping of a susceptibility locus for Crohn's disease on chromosome 16.

Authors:  J P Hugot; P Laurent-Puig; C Gower-Rousseau; J M Olson; J C Lee; L Beaugerie; I Naom; J L Dupas; A Van Gossum; M Orholm; C Bonaiti-Pellie; J Weissenbach; C G Mathew; J E Lennard-Jones; A Cortot; J F Colombel; G Thomas
Journal:  Nature       Date:  1996-02-29       Impact factor: 49.962

5.  Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans.

Authors:  E Louis; D Franchimont; A Piron; Y Gevaert; N Schaaf-Lafontaine; S Roland; P Mahieu; M Malaise; D De Groote; R Louis; J Belaiche
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

6.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

Authors:  J M Reimund; C Wittersheim; S Dumont; C D Muller; J S Kenney; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

7.  TAP gene transporter polymorphism in inflammatory bowel diseases.

Authors:  D Heresbach; M Alizadeh; J F Bretagne; A Dabadie; J F Colombel; M Pagenault; N Heresbach-Le Berre; B Genetet; M Gosselin; G Semana
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

8.  Nuclear factor-kappa B repression in antiinflammation and immunosuppression by glucocorticoids.

Authors:  B van der Burg; J Liden; S Okret; F Delaunay; S Wissink; P T van der Saag; J A Gustafsson
Journal:  Trends Endocrinol Metab       Date:  1997 May-Jun       Impact factor: 12.015

9.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.

Authors:  A G Wilson; N de Vries; F Pociot; F S di Giovine; L B van der Putte; G W Duff
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  20 in total

1.  A meta-analysis on the association between three promoter variants of TNF-α and Crohn's disease.

Authors:  Cui Xie; Xiao Feng Liu; Mao Sheng Yang
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

2.  Graves' disease and gene polymorphism of TNF-α, IL-2, IL-6, IL-12, and IFN-γ.

Authors:  Mehdi Anvari; Omid Khalilzadeh; Alireza Esteghamati; Fatemeh Momen-Heravi; Mahdi Mahmoudi; Shadi Abdar Esfahani; Armin Rashidi; Aliakbar Amirzargar
Journal:  Endocrine       Date:  2010-03-05       Impact factor: 3.633

3.  Circulating cell-derived microparticles in Crohn's disease.

Authors:  Patrick Chamouard; Dominique Desprez; Bénédicte Hugel; Corinne Kunzelmann; Carole Gidon-Jeangirard; Michel Lessard; René Baumann; Jean-Marie Freyssinet; Lélia Grunebaum
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 4.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Genetics of inflammatory bowel disease: current status and future directions.

Authors:  Thomas D Walters; Mark S Silverberg
Journal:  Can J Gastroenterol       Date:  2006-10       Impact factor: 3.522

Review 6.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

Review 7.  Genetics of inflammatory bowel disease: the role of the HLA complex.

Authors:  Tariq Ahmad; Sara-E Marshall; Derek Jewell
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

8.  Functional interaction of CARD15/NOD2 and Crohn's disease-associated TNFalpha polymorphisms.

Authors:  Ylva Linderson; Francesca Bresso; Eva Buentke; Sven Pettersson; Mauro D'Amato
Journal:  Int J Colorectal Dis       Date:  2005-03-31       Impact factor: 2.571

Review 9.  Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning.

Authors:  Chang-Qing Zheng; Gang-Zheng Hu; Zhao-Shu Zeng; Lian-Jie Lin; Gin-Ge Gu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

10.  Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease.

Authors:  Agnes Vatay; László Bene; Agota Kovács; Zoltán Prohászka; Csaba Szalai; László Romics; Béla Fekete; István Karádi; George Füst
Journal:  Immunogenetics       Date:  2003-06-14       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.